RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.
Am J HematolMay 12, 2026 (epub)
Cong Li, Tao Lei, Xiyue Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
The RCLARITY trial, a prospective Phase II study, evaluated the efficacy and safety of a chemotherapy-free regimen combining rituximab, lenalidomide, and chidamide in 28 adults with relapsed/refractory angioimmunoblastic T-cell lymphoma (AITL). The study found an overall response rate of 71.4% and a median overall survival of 17.6 months.
Key findings
- Overall response rate was 71.4%, with a complete remission rate of 32.1%.
- Median progression-free survival was 5.5 months (95% CI, 3.5-7.6).
- Median overall survival was 17.6 months (95% CI, 10.3-24.8).
- 50% of patients with clonal Ig rearrangements achieved progression-free survival > 16 months.
Why it matters
This study highlights a promising treatment option for patients with relapsed/refractory AITL, a condition with historically poor outcomes. The regimen's efficacy and manageable toxicity profile may improve patient care in this challenging population.